Publications by authors named "M C Pepin"
Background: The worldwide population is ageing and self-arm can be prevented with many techniques. Among them coercive measure consisting of physical restraint (PR) is one of the techniques. This study aims to assess the effects of the biological sex on the long-term survival after PR in geriatric patients during the initial emergency department (ED) visit.
View Article and Find Full Text PDFNovel biomarkers are needed to better identify-and distinguish-heart failure with preserved ejection fraction (HFpEF) from other clinical phenotypes. The goal of our study was to identify epigenetic-sensitive biomarkers useful to a more accurate diagnosis of HFpEF. We performed a network-oriented genome-wide DNA methylation study of circulating CD4 T lymphocytes isolated from peripheral blood using reduced representation bisulfite sequencing (RRBS) in two cohorts (i.
View Article and Find Full Text PDFArticle Synopsis
- People with chronic kidney disease (CKD) face a higher risk of cognitive impairment (CI), and this study investigates the link between anticholinergic medications and cognitive performance in CKD patients.
- The research involved a prospective cohort study of 3007 nephrology outpatients, where data on medication prescriptions and cognitive function were collected over five years.
- Findings revealed that over half of the participants were prescribed anticholinergic drugs, with those having a high anticholinergic burden more likely to experience cognitive impairment, particularly if they had a history of neurological disorders or were on multiple medications.
Translational research on cognitive impairment in chronic kidney disease.
Nephrol Dial Transplant
October 2024
Article Synopsis
- * Both traditional risk factors (like diabetes and high blood pressure) and kidney-specific factors (such as uremic toxins and chronic inflammation) can damage the blood-brain barrier and promote neuroinflammation, leading to cognitive impairments.
- * Recent animal model studies suggest new prevention and treatment strategies, focusing on the role of the blood-brain barrier, physical activity, and innovative therapies like SGLT2 inhibitors and GLP-1 receptor agonists in addressing cognitive decline in kidney disease.